ATE185803T1 - N-hydroxy-harnstoff-derivate als entzündunghemmende mittel - Google Patents

N-hydroxy-harnstoff-derivate als entzündunghemmende mittel

Info

Publication number
ATE185803T1
ATE185803T1 AT95921115T AT95921115T ATE185803T1 AT E185803 T1 ATE185803 T1 AT E185803T1 AT 95921115 T AT95921115 T AT 95921115T AT 95921115 T AT95921115 T AT 95921115T AT E185803 T1 ATE185803 T1 AT E185803T1
Authority
AT
Austria
Prior art keywords
pct
hydroxy
inflammatory agents
urea derivatives
sec
Prior art date
Application number
AT95921115T
Other languages
English (en)
Inventor
Akemi Ando
Rodney W Stevens
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE185803T1 publication Critical patent/ATE185803T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT95921115T 1994-05-19 1995-06-07 N-hydroxy-harnstoff-derivate als entzündunghemmende mittel ATE185803T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP12810594A JP3179286B2 (ja) 1994-05-19 1994-05-19 Ｎ−ヒドロキシ尿素系抗炎症剤
CA002223023A CA2223023C (en) 1994-05-19 1995-06-07 N-hydroxyureas as antiinflammatory agents
PCT/JP1995/001127 WO1996040659A1 (en) 1994-05-19 1995-06-07 N-hydroxyureas as antiinflammatory agents

Publications (1)

Publication Number Publication Date
ATE185803T1 true ATE185803T1 (de) 1999-11-15

Family

ID=27170556

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95921115T ATE185803T1 (de) 1994-05-19 1995-06-07 N-hydroxy-harnstoff-derivate als entzündunghemmende mittel

Country Status (19)

Country Link
US (1) US5814648A (de)
EP (1) EP0832078B1 (de)
JP (2) JP3179286B2 (de)
AT (1) ATE185803T1 (de)
AU (1) AU705505B2 (de)
BR (1) BR9502072A (de)
CA (1) CA2223023C (de)
CZ (1) CZ286331B6 (de)
DE (1) DE69512940T2 (de)
DK (1) DK0832078T3 (de)
ES (1) ES2138211T3 (de)
FI (1) FI974444A (de)
GR (1) GR3032301T3 (de)
HU (1) HUT77950A (de)
IL (1) IL113706A (de)
NO (1) NO310288B1 (de)
NZ (1) NZ287551A (de)
PL (1) PL179853B1 (de)
WO (1) WO1996040659A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548419A1 (de) * 1995-12-22 1997-06-26 Bayer Ag Substituierte Thiazoline
EP1554572B1 (de) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
JP2008534542A (ja) 2005-03-31 2008-08-28 ユセベ ファルマ ソシエテ アノニム オキサゾール部分又はチアゾール部分を含む化合物、それらの製造方法及びそれらの使用
EP2671508B1 (de) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-Informatiksystem
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2021214048A1 (en) * 2020-04-20 2021-10-28 Johann Wolfgang Goethe-Universität Frankfurt am Main Dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960005541B1 (ko) * 1990-07-25 1996-04-26 애보트 래보러터리즈 리폭시게나제 억제 활성을 갖는 아세틸렌 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
JP2528741B2 (ja) * 1991-01-09 1996-08-28 ファイザー製薬株式会社 オキサゾ―ル、チアゾ―ルおよびイミダゾ―ル化合物
JPH07100687B2 (ja) * 1991-06-13 1995-11-01 ファイザー製薬株式会社 新規なｎ−ヒドロキシ尿素化合物および組成物
US5288751A (en) * 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
CA2160140C (en) * 1993-04-07 1999-03-16 Rodney William Stevens Cycloalkylhydroxyureas and their use as lipoxygenase inhibitors

Also Published As

Publication number Publication date
WO1996040659A1 (en) 1996-12-19
NO975726L (no) 1998-02-03
JPH10506649A (ja) 1998-06-30
PL324012A1 (en) 1998-04-27
PL179853B1 (pl) 2000-11-30
EP0832078B1 (de) 1999-10-20
DK0832078T3 (da) 2000-04-25
CA2223023C (en) 2001-07-17
AU2629495A (en) 1996-12-30
NO310288B1 (no) 2001-06-18
US5814648A (en) 1998-09-29
NZ287551A (en) 1999-02-25
GR3032301T3 (en) 2000-04-27
FI974444A0 (fi) 1997-12-05
FI974444A (fi) 1998-02-04
HUT77950A (hu) 1998-12-28
EP0832078A1 (de) 1998-04-01
CZ382497A3 (cs) 1999-03-17
ES2138211T3 (es) 2000-01-01
CZ286331B6 (cs) 2000-03-15
BR9502072A (pt) 1996-04-09
JPH07309849A (ja) 1995-11-28
CA2223023A1 (en) 1996-12-19
IL113706A (en) 1999-08-17
NO975726D0 (no) 1997-12-05
MX9709986A (es) 1998-03-29
JP3179286B2 (ja) 2001-06-25
DE69512940D1 (de) 1999-11-25
DE69512940T2 (de) 2000-02-17
AU705505B2 (en) 1999-05-27
IL113706A0 (en) 1995-08-31

Similar Documents

Publication Publication Date Title
ZA919317B (en) Novel hydroxamic acid and N-hydroxyurea derivatives and their use.
ATE185803T1 (de) N-hydroxy-harnstoff-derivate als entzündunghemmende mittel
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
ATE309803T1 (de) Sphingomyelinase inhibitoren als wirkstoffe mit antiapoptotischer und antiseptischer wirkung
FI932654A (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
DE69413831D1 (de) Phenoxyphenylcyclopentenyl-hydroxyharnstoffe
ATE190845T1 (de) Rektale flunisolid-zubereitung zur behandlung entzündlicher darmerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee